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survival (LPFS) rate was 75.8% at median follow-up of 19 months, and 
1- and 2-year LPFS was 93.8%, 73.2% respectively. Overall survival 
was relatively worse, 90.8% at 1 year and 51.9% at 2 year, because 
most of patients had a medical problem in lung or heart. While all pa-
tients developed grade 1 radiation pneumonitis within 3 months of SRS 
treatment, none developed symptomatic or serious late complications.
Conclusions: The results demonstrate that fractionated SRS on con-
secutive days was both effective and convenient for treating technically 
operable, but medically inoperable patients with early stage NSCLC. 
This treatment appears to offer comparable local disease control with-
out serious complications.
Novel Therapeutics: Surgery: RFA Etc.
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Introduction: The surgical treatment of pulmonary metastases is a pro-
cedure of proved therapeutic effectiveness, with a 5 years survival rate 
ranging from 20 to 40%. In the last years we proposed, as an alternative 
approach, radiofrequency thermal ablation of pulmonary metastases to 
patients not considered surgical candidates.
Materials and Methods: From 1990 to the 2006 we performed 138 
surgical resection in 118 patients with pulmonary metastases ( 20 pa-
tients were operated two times). The range of the disease free interval 
between the presentation of the primary tumor and that of metastases 
(DFI) was of 28,68 months (range 0-19 years). The patient’s age range 
was 21-80 years (average 50,1). We removed 219 metastases (average 
1,58; range: 1-7), all conﬁrmed by hystological examination. The size 
of the lesions ranged from 1 to 8 cm, (average 2,58 cm). The average 
hospital stay was 8,1 days (range 6-24); we estimated also the post-op-
erative pain and the complication rate (25 cases, 18.1% respectively). 
We did not observe any intra-operating mortality. From 2003 to 2005 
24 patients ( average age 69,5 years, range 66-75 years) with pulmo-
nary metastases (maximum diameter 3,5 cm.) not considered surgical 
candidates, underwent CT guided percutaneous radiofrequency thermal 
ablation (RF). All these patients underwent a CT/PET examination 
pre-treatment, repeated within 24h from the thermoablation in one day-
surgery. 
Results: The DFI was of 8,74 months (range 0-27 months), while aver-
age survival after surgical resection was of 24,37 months (range 2-10 
years). Until today 30 patients are alive, with an average follow-up of 
65,8 months (range 12 months-15 years); only one patient had disease 
recurrence. The 1 year survival rate was 76.2%, the 3 years 44.1%, the 
5 years 28.3% and the 10 years 16,2%. We considered several prognos-
tic factors: hystology, DFI, number of metastases, number of resec-
tions, lesion mono/bilaterality, type of resection and the diameter of the 
metastases. The data regarding patients treated with RF are preliminary. 
The treatment in 100% of the cases was feasible and safe, with no sig-
niﬁcant morbidity or mortality. The six months survival rate was 100%, 
the 1 year 75% and the 3 year 12,5%. The use of the CT/PET fusion 
imaging after the procedure always evidenced the absence of metabolic 
activity in the treated metastatic lesion. 
Conclusions: The surgery of the pulmonary metastases is today a valid 
procedure for patients at M1 stage with good general and respira-
tory conditions and with an effective control of primary tumor. The 
percutaneous radiofrequency thermal ablation could be an important 
alternative for the treatment of pulmonary metastases in patients not 
considered to be surgical candidates.
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Purposes: The aim of this study was to evaluate the diagnostic efﬁcacy 
of positron emission tomography (PET)/computed tomography (CT) in 
the detection of residual tumor after cryoablation of pulmonary tumors 
regardless of primary or metastatic lesions. 
Materials and Methods: Eight patients with 10 lesions (mean size: 
4.9 cm) were evaluated in this study. Total 25 procedures of cryoabla-
tion were preformed and 23 PET/CT examinations (including pre and 
post ablation) were analyzed. The patients had PET/CT before and after 
ablation using [18F]-2-ﬂuoro-2-deoxy-D-glucose. CT images were 
interpreted, not correlated with the results of PET-CT scan. PET-CT im-
ages were also evaluated and measured SUV (1hr, 2hr, retention index 
were acquired. We acquired the percent change of SUV according to 
the following equation; RI (Retention Index) = (SUV 1h-SUV2h)x100/
SUV 1h The accuracy for detection of residual tumor by the different 
imaging modalities following ablation was assessed.
Results: Eight patients with a mean age of 64.8 (range 52-73) years 
were reviewed. The histopathology was primary lung cancers (8, 
squamous -6, adenocarcinoma -2, metastatic cancers (2, from rectum 
and trachea). The mean follow-up period was 194 days. Two patients 
had residual tumor after ablation, six patients were revealed near total 
cavitation developed and no evidence of hypermetabolic foci in the 
cavitary lesion on 2nd follow up PET/CT The above ﬁnding were cor-
related with enhancing solid component on enhanced CT scan within 2 
weeks of PET-CT scan. The difference of the HU between pre and post 
CE study were correlated with SUV (standardized uptake value) for the 
target lesion on PET-CT.
Conclusion: PET-CT has potential roles in the evaluation for the 
residual viable tumors after cryoablation and has been proved to be 
superior to CT alone when assessing the pulmonary malignant lesions 
after cryoablation.
